2019
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV
Oldfield BJ, McGinnis KA, Edelman EJ, Williams EC, Gordon AJ, Akgün K, Crystal S, Fiellin LE, Gaither JR, Goulet JL, Korthuis PT, Marshall BDL, Justice AC, Bryant K, Fiellin DA, Kraemer KL. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. Journal Of Substance Use And Addiction Treatment 2019, 109: 14-22. PMID: 31856946, PMCID: PMC6982467, DOI: 10.1016/j.jsat.2019.11.002.Peer-Reviewed Original ResearchConceptsAlcohol use disorderUse disordersHIV statusUninfected individualsVeterans Aging Cohort Study (VACS) dataEvidence-based medicationsNew alcohol use disorderPrevalence of initiationMultivariable logistic regressionPredictors of initiationFacility-level predictorsCohort study dataMedication initiationPrescription fillsMultivariable analysisBlack raceTreatment gapDecreased oddsNew diagnosisPLWHOlder ageLogistic regressionMedicationsHIVSpecific subpopulations
2014
End-Stage Renal Disease Among HIV-Infected Adults in North America
Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester C, Bosch R, Crane H, Eron J, Gill M, Horberg M, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, AIDS F, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Althoff K, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases 2014, 60: 941-949. PMID: 25409471, PMCID: PMC4357817, DOI: 10.1093/cid/ciu919.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSex-standardized incidence ratiosRisk of ESRDDiabetes mellitusESRD casesBlack racePredictors of ESRDNorth American AIDS Cohort CollaborationHepatitis C virus coinfectionC virus coinfectionESRD risk factorsIncident ESRD casesHuman immunodeficiency virusHigh viral loadMajority of casesCohort CollaborationVirologic suppressionESRD incidencePrior AIDSRenal transplantViral suppressionInject drugsRenal diseaseVirus coinfectionBlack patients
2011
Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. The Journal Of Infectious Diseases 2011, 204: 893-901. PMID: 21849286, PMCID: PMC3156918, DOI: 10.1093/infdis/jir421.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationInjection drug useHIV-1 RNAHuman immunodeficiency virusHAART initiationTuberculosis riskBaseline CD4Therapy initiationMale sexNonwhite raceHispanic ethnicityDrug useBaseline HIV-1 RNAMonths of HAARTLow-incidence settingsProportional hazards modelActive tuberculosisLymphocyte countParametric survival modelsTuberculosis screeningImmunodeficiency virusBlack raceLymphocytes/Risk factors
2006
Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects
BUTT AA, JUSTICE AC, SKANDERSON M, GOOD C, KWOH CK. Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects. Alimentary Pharmacology & Therapeutics 2006, 24: 585-591. PMID: 16907891, DOI: 10.1111/j.1365-2036.2006.03020.x.Peer-Reviewed Original ResearchConceptsHepatitis C virus (HCV) treatmentC virus treatmentHepatitis C virusHepatitis C virus-infected subjectsHCV-HIVVirus-infected subjectsC virusVirus treatmentTreatment ratesVeterans Affairs National Patient Care DatabaseDrug useNational Patient Care DatabaseImpact of comorbiditiesEffect of comorbidityPatient Care DatabaseICD-9 codesCoinfected subjectsHispanic racePharmacy dataBlack raceCare databaseMajor depressionPsychiatric illnessMild depressionBipolar disorder